Skip to main content

Table 1 Physical profiles of control, placebo-group, and DOCA-salt group rats

From: Transiently proliferating perivascular microglia harbor M1 type and precede cerebrovascular changes in a chronic hypertension model

Group

Body weight (g)

Systolic blood pressure (mmHg)

Heart rate (/min)

Symptoms

Control

0W

165 ± 4.3

113.0 ± 2.8

427.3 ± 38

None

Placebo

2W

261 ± 3.9*

116.3 ± 3.4

414.3 ± 31

None

3W

295 ± 16*

125.0 ± 3.7

412.3 ± 33

None

4W

330 ± 11*

130.0 ± 7.3

413.0 ± 12

None

DOCA

2W

250.3 ± 8.3*

183.3 ± 24*

416.0 ± 50

None

3W

253.0 ± 30*

204.3 ± 18*

407.3 ± 9.5

Hemiparesis, bleeding from the tail vein, and loss of appetite

4 W

225.0 ± 14*

207.0 ± 30*

450.0 ± 29

Severe inactive state

  1. Rats administrated with DOCA-salt or placebo for 2 weeks (DOCA2W or Placebo2W), 3 weeks (DOCA3W or Placebo3W), and 4 weeks (DOCA4W or Placebo4W) were analyzed. Values are expressed as means ± SEM (n = 3 in each group). Statistical significance was expressed as *p < 0.05 relative to the control by using t test
Back to article page

Journal of Neuroinflammation

ISSN: 1742-2094